# To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions

> **NCT00946686** · PHASE1 · COMPLETED · sponsor: **Sandoz** · enrollment: 52 (actual)

## Conditions studied

- Rheumatoid Arthritis
- Psoriatic Arthritis

## Interventions

- **DRUG:** Leflunomide 20 mg Tablets (Geneva Pharmaceutical)
- **DRUG:** Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)

## Key facts

- **NCT ID:** NCT00946686
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-09
- **Final completion:** 2002-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2017-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946686, "To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT00946686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*